Arise... Sir Kevin Sinfield. The rugby league legend, who has raised over £11 million for MND causes, inspired by his late friend and team-mate Rob Burrow, has become Sir Kevin in the King’s Birthday Honours list. He spoke to Sally Nugent for #BBCBreakfast bbc.co.uk/sport/articles/c07…

📝 Narrative Review: Low-dose #Lithium exposure is linked to neuroprotective effects, reduced #Dementia risk, and cognitive stabilization in mild cognitive impairment, supporting further clinical evaluation. ja.ma/43styN4

The test that exposes nerve and muscle dysfunction associated with MND. My second conversation on Project 100 with one of Australia’s best neurologists and neuroscientists is out now! Matthew Kiernan AM is CEO of NeuRA (Neuroscience Research Australia) and one of the nation’s leading neurologists tackling the growing dementia crisis. Search Straight Talk with Mark Bouris for a link to the full episode. @nervecentrals

'I feel like I arrive in this MND space in a much more hopeful space because of the amazing work Doddie Weir did' Former England rugby union captain Lewis Moody, who was diagnosed with MND last year, spoke to #BBCBreakfast about his seven-day cycling challenge in aid of the My Name'5 Doddie Foundation - a 500-mile trip from Newcastle to Twickenham, to deliver the match ball for the Prem final in June bbc.co.uk/sport/rugby-union/…

There was a wide array of emotions on Daniher's Way in Melbourne when NeuRA's CEO, Scientia Professor Matthew Kiernan AM, joined hundreds in the "Walk to the G" - part of the first Big Freeze event since its pioneer, FightMND founder Neale Daniher, recently passed away. "A poignant Walk to the G, along Daniher’s Way, a great tribute to Neale Daniher... transformation of the MND landscape, nationally and globally, thanks to FightMND," said Professor Kiernan. The turnout showed the coming together of the community in support of Neale and his family, and support for Motor Neurone Disease research and clinical trials.

Integrating genetic and pathological data increased diagnostic accuracy and identified ancestry-related differences in #ParkinsonDisease, supporting biologically informed diagnostic tools and future pathology-targeted therapeutic trials. ja.ma/49N7lN9

This study found that human IgLON5 antibodies reduce neuronal IgLON5 clusters and cause motor dysfunction in mice. Learn more: hubs.la/Q04klsD40

A poignant Walk to the G, along Daniher’s way, a great tribute to @NealeDaniher | Transformation of the #MND landscape, nationally & globally, thanks to @FightMND - collaboration, industry partnerships, with improved outcomes, research & clinical trials @neuraustralia

This study helps identify stroke and heart attack risk in patients. My second conversation on Project 100 with one of Australia’s best neurologists and neuroscientists is out now! Matthew Kiernan AM is CEO of NeuRA (Neuroscience Research Australia) and one of the nation’s leading neurologists tackling the growing dementia crisis. Search Project 100 wherever you get your podcasts, plus this ep is on our Straight Talk channels too. @nervecentrals

Corriveau-Lecavalier et al. show that patterns of default mode network dysfunction predict future conversion to amyloid positivity, mild cognitive impairment, and dementia, emphasizing the role of network dyshomeostasis in Alzheimer’s disease. shorturl.at/frhmE

A brain expert explains how Vascular Dementia changes brain and motor function. My second conversation on Project 100 with one of Australia’s best neurologists and neuroscientists is out now! Matthew Kiernan AM is CEO of NeuRA (Neuroscience Research Australia) and one of the nation’s leading neurologists tackling the growing dementia crisis. Search Project 100 wherever you get your podcasts, plus this ep is on our Straight Talk channels too. @nervecentrals

Acute Kidney Injury and Risk of Adverse Neurocognitive Outcomes: A Systematic Review and Meta-Analysis Acute Kidney Injury and Risk of Adverse Neurocognitive Outcomes hubs.la/Q04j_Y1W0 #Dementia #Stroke

June's NeuRA All-Staff Meeting shone a topical spotlight on Motor Neurone Disease, current research and the experience of people living with it every day, in the lead up to MND Awareness Day on June 21. Clinical Trials Specialist Eleanor Ramsey, part of the Kiernan Group at NeuRA, shared an update on the team’s work and impact. Additionally we were joined by Michael O’Hehir, who is living with MND and has been involved in the RESCUE-ALS Trial, speaking on his experience and the importance of trials like these. We also had an in-conversation with Director of Communications Tom Smithies and NeuRA’s new Research Strategy and Quality Manager, Alex Economides, on his journey that led him to NeuRA, as well as CEO Professor Matthew Kiernan AM updating on what is happening in and around NeuRA and the research sphere.

Today, we play for No. 4. Today, we play for the cure. #LouGehrigDay

The Autumn issue of NeuRA Magazine is out now! - Find out the latest work to tackle Parkinson’s Disease - We introduce our NeuRA Quest Scholars - Ask a researcher what hair can tell us about stress in autism, and - Spend five minutes with NeuRA supporter, Malcolm Ginn. You can read the stories and more here: neura.edu.au/magazines/the-n…

June is migraine awareness month. Migraine affects an estimated 1.1 billion people worldwide and is one of the leading causes of disability globally. Its burden is especially pronounced among young adults, with prevalence increasing through puberty, peaking at around 40 years of age, and occurring more frequently in women than men. Explore more here: neurotorium.org/slidedeck/mi…

Minogue & Zouridakis et al. studied the brains of people with dementia and FTLD-PSP or FTLD-CBD. They found that PSP and CBD show distinct patterns of selective vulnerability, with tau pathology predominantly affecting glia in PSP and neurons in CBD. shorturl.at/WPMzh

A New Motor Neuron Disease (MND) drug is showing reductions in key disease markers, slowing the progression of the disease in patients with a particular genetic mutation and providing hope to families. Through monthly injections, the new drug binds to messenger RNA, reducing the number of harmful SOD1 (Superoxide Dismutase 1) proteins that build up in the nerve cells and which cause MND in up to 2% of all cases. The growing urgency of treating the disease as well as the promising data from the drug, has prompted the Therapeutic Goods Administration to grant provisional approval of the drug, enabling Australian patients’ faster access. Speaking with Channel 9, NeuRA CEO Professor Matthew Kiernan AM emphasised the importance of early intervention leading to more positive outcomes when it comes to MND. "The availability of a targeted treatment reinforces the need for clinicians to act with urgency; any suspicion of MND should prompt immediate referral to a neurologist or specialist centre," said Professor Kiernan. You can read the whole story here: nine.com.au/australia-news/h… @nervecentrals

Blood test can identify signs of Alzheimer’s Disease decades before symptoms, suggests new study in The Lancet. Find out more: spkl.io/60117B6VS

A stress hormone may help switch the young brain out of its most flexible state, through a pathway that starts outside neurons. @harvardmed @nature medicalxpress.com/news/2026-…